Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Open Access

Peer-reviewed

Research Article

Shuyan Gu,

Affiliation Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
⨯
Yiming Mu,

Affiliation Department of Endocrinology and Metabolism, Chinese PLA General Hospital, Chinese PLA Medical College, Beijing, China
⨯
Suodi Zhai,

Affiliation Department of Pharmacy, Peking University Third Hospital, Beijing, China
⨯
Yuhang Zeng,

Affiliation Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
⨯
Xuemei Zhen,

Affiliation Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
⨯
Hengjin Dong

* E-mail: donghj@zju.edu.cn

Affiliation Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China
⨯

Reader Comments (0)

Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
HbA1c
Is the Subject Area "HbA1c" applicable to this article?

Thanks for your feedback.
Urinary tract infections
Is the Subject Area "Urinary tract infections" applicable to this article?

Thanks for your feedback.
Gastrointestinal infections
Is the Subject Area "Gastrointestinal infections" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.